Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)?
The gastric cancer with peritoneal metastases still represents a serious problem in the oncological surgery, whereas the peritoneal metastases arising from colorectal cancer can be successfully treated using a multimodal therapy concept consisting of systemic chemotherapy, cytoreductive surgery and...
Main Authors: | Blaj Sebastian, Piso Pompiliu |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2017-12-01
|
Series: | Current Issues in Pharmacy and Medical Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1515/cipms-2017-0040 |
Similar Items
-
Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
by: Falla-Zuniga Luis Felipe, et al.
Published: (2023-12-01) -
Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)
by: Sohan Lal Solanki, et al.
Published: (2019-01-01) -
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
by: Loss Martin, et al.
Published: (2004-06-01) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis
by: Seung Jae Roh, et al.
Published: (2020-02-01) -
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)
by: Koen P. Rovers, et al.
Published: (2019-04-01)